Life Biosciences announced today that the first participant has been dosed in the Phase 1 trial of ER-100, the partial epigenetic reprogramming therapy whose trial clearance we covered in January. It is, as far as we can tell, the first time a reprogramming therapy has been given to a human being in a trial. The trial registry describes what that means: an open-label, non-randomized study of about 18 people aged 40 to 85 with glaucoma or a form of optic-nerve stroke, each receiving a single injection into one eye followed by eight weeks of an oral antibiotic that switches the therapy on. The primary outcomes are adverse events, dose-limiting toxicities and ocular safety at eight and sixteen weeks, with follow-up planned for up to five years. Visual function is measured, but it is secondary. This is a day worth marking. It is also a day to be precise about.
What eighteen people can tell you. Whether the therapy is tolerated at two doses, what the immune system does, and which dose to carry into a larger study. They cannot tell you whether sight improves, because the study is not designed or sized to show that, and because there is no control group. A good Phase 1 result is "nothing bad happened"; a bad one ends the program. The company's co-founder describes the study as the first opportunity to test whether restoring epigenetic information can ameliorate human disease — a fair description of the question, not an answer to it. The animal data behind the trial are the company's, and the human data do not exist yet. They are being collected, one eye at a time, starting today.
Loree’s takePatients hear "first human dosed" and picture a breakthrough. What happened today is that a volunteer with a serious eye disease accepted an unknown risk so that a question could be asked. That is admirable and it is not a result. When a company selling "cellular rejuvenation" supplements cites this trial, remember what the trial measures: safety, in eighteen eyes, over a decade of follow-up. Nobody in a supplement aisle has signed up for that.
Ben’s takeThis is the pace of the real thing. January: permission. June: one person. 2027: a readout about tolerability. Then, if all goes well, a larger trial, and another, in one disease, in one organ. A reader who understands that timeline is immune to most of what the longevity industry sells, because the industry's entire pitch is that the timeline does not apply to its products. It does. Today is what the timeline looks like when it is followed.
What to watch. The safety readout, expected next year, and whether it names a dose for a Phase 2. Every other mention of this trial — in a product description, a podcast, a pitch — is borrowing a single injection in a single eye to sell something that has not been injected into anyone.
"First patient dosed" means a safety question was asked. Hold every product using this science to the answer, which arrives next year at the earliest.